Notice to Convene an Extraordinary General Meeting

NEXT STORY
Une présentation de dernière minute au congrès de l’ESMO montre qu’une monothérapie par Libtayo® (cemiplimab) augmente la survie globale des patients atteints d’un cancer du poumon non à petites cellules dont 50 % ou plus des cellules tumor
PREV STORY
TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

author_avatar
NASDAQ Market News

Global Residential Air Purification Equipment Market Report 2020: COVID-19 Crisis Presents Opportunity for Residential Air Purification Systems

author_avatar
NASDAQ Market News

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

author_avatar
NASDAQ Market News